CCXI and AMGN Related Headlines
Go Back- AMGEN names Thomas Dittrich as new CFO as Peter Griffith retires
- AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
- AMGEN announces $300 million US manufacturing investment
- AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
- AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
- /C O R R E C T I O N -- Amgen/
- AMGEN announces CTO David Reese retirement and leadership changes
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
- N/a
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
- REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
- AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
CCXI and AMGN Related Press Releases
Go Back- AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
- AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
- /C O R R E C T I O N -- Amgen/
- AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
- REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
- AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
